Hinge Health (HNGE) has drawn fresh attention after recent share price moves, with the stock up 25% over the past month and 68% over the past 3 months, prompting closer scrutiny from investors.

Against this backdrop, Hinge Health’s recent momentum stands out, with a 24.62% 1 month share price return and 68.30% 3 month share price return, while the 1 year total shareholder return sits at 57.59%. This indicates strong recent interest building around the stock.

If you are tracking how healthcare technology stories like Hinge Health are gaining traction, it may be worth widening your search to other AI driven healthcare opportunities via the 38 healthcare AI stocks.

With Hinge Health delivering rapid share price gains and carrying a value score of 2 alongside an estimated 16% gap to analyst targets, investors now face a key question: is there still upside on the table, or is the market already pricing in future growth?

Most Popular Narrative: 59% Overvalued

Compared with Hinge Health’s last close at $68.85, the most followed narrative fair value of $43.40 implies a steep valuation gap that hinges on specific long term assumptions.

The assumed bearish price target for Hinge Health is $43.4, which represents up to two standard deviations below the consensus price target of $57.94. This valuation is based on what can be assumed as the expectations of Hinge Health's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

Curious what kind of revenue ramp, margin lift and earnings profile underpin that lower fair value for Hinge Health, and how those assumptions are stretched over time.

Result: Fair Value of $43.40 (OVERVALUED)

However, Hinge Health could still surprise this narrative if its reported 83% to 85% gross margins hold up and the HingeSelect buildout begins to gain meaningful traction.

Another View: SWS DCF Signals Undervaluation

While the bearish narrative characterizes Hinge Health as 59% overvalued at a fair value of $43.40, the SWS DCF model points in the opposite direction. Under this framework, HNGE at $68.85 is compared with an estimated future cash flow value of $283.21, suggesting a discount of about 75.7%. This contrast raises the question of which framework an investor might consider when focusing on cash generation.

For a closer look at how this cash flow based view is constructed, including the key inputs and sensitivities, take a moment to review the SWS DCF model in detail, starting with the Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Hinge Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

If this mix of optimism and caution around Hinge Health has you thinking, act quickly. Review the underlying data for yourself and weigh up the 3 key rewards.

Looking for more investment ideas beyond Hinge Health?

If Hinge Health has caught your eye, do not stop there. Broaden your watchlist now or you may miss opportunities that fit your style even better.

• Target potential mispriced opportunities by scanning 44 high quality undervalued stocks, which combines quality fundamentals with attractively low market expectations.
• Strengthen your focus on resilience by reviewing 66 resilient stocks with low risk scores, which scores well on financial stability and business risk metrics.
• Spot tomorrow’s potential standouts early by using the screener containing 19 high quality undiscovered gems before they appear on everyone else’s radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.